

Instant Claims

PU3616US2

In the Claims:

Please cancel claims 1-11, 14, 17-19 and 22-35 without prejudice thereto. Please amend the claims as follows:

Claims 1 - 11 (canceled)

12. (currently amended) A method ~~for regulating of increasing~~ I-BABP expression in a mammal ~~which comprises activating or inhibiting the Farnesoid X Receptor~~ comprising administering an effective amount of a non-steroidal Farnesoid X Receptor agonist to said mammal.

13. (currently amended) The method of claim 12, ~~which comprises binding an activating amount of chenodeoxycholic acid to the Farnesoid X Receptor~~ where said Farnesoid X Receptor agonist is GW4064.

14. (canceled)

15. (currently amended) A method of ~~regulating the bile transport system~~ increasing bile acid transport from the intestinal lumen across the intestinal membrane in a mammal which comprises ~~activating the Farnesoid X Receptor with a binding ligand~~ administering an effective amount of a non-steroidal Farnesoid X Receptor agonist to said mammal.

16. (currently amended) The method of claim 15, wherein said FXR agonist is GW4064 ~~the binding ligand is GW4064, chenodeoxycholic acid, lithocholic acid, deoxycholic acid, or a glycine or taurine conjugated conjugate derivative thereof.~~

17-19 (cancelled)

20. (currently amended) A method of lowering serum triglycerides ~~treating in a mammal a disease which is affected by cholesterol, triglyceride, or bile acid levels~~

12, 13, 15, 16, 20, 21 pending

3

I 12, 13

II 15, 16

III 20

IV 21

broken up more
w/ various compounds

all methods which differ b/c ...
and use different compounds which vary

comprising administering to a mammal in need of such treatment ~~a therapeutically effective~~ an effective serum triglyceride lowering amount of a non-steroidal agonist ligand for Farnesoid X Receptor.

21. (currently amended) A method of treating ~~atherosclerosis, gallstone disease, lipid disorders, obesity or a cardiovascular disorder~~ in a mammal in need of such treatment, comprising administration of a therapeutically effective amount of a ~~compound which was identified by the method of Claim 4~~ non-steroidal FXR agonist.

22-35 (canceled)